title: CNS drug development - lost in translation?
abstract: CNS drug development is characterized by an especially high attrition rate, despite clear unmet medical needs in the field of neuro-pharmacology and significant investment in R of novel CNS drug treatments. Here, we overview the issues underlying the intrinsic difficulty of CNS drugs development, including obstacles of pharmacokinetic nature and lack of predictivity of preclinical tests. We highlight current efforts to overcome these limitations, with an emphasis on modeling opportunities towards early recognition of CNS candidates (stressing the possibilities of multi-target directed ligands or "magic shotguns") and different approaches to improve CNS bioavailability.
authors.affiliation: Medicinal Chemistry, Department of Biological Sciences, Faculty of Exact Sciences, National University of La Plata, Buenos Aires, Argentina. alantalevi@hotmail.com
authors.forename: A
authors.initials: A
authors.lastname: Talevi
authors.forename: C L
authors.initials: CL
authors.lastname: Bellera
authors.forename: M
authors.initials: M
authors.lastname: Di Ianni
authors.forename: M
authors.initials: M
authors.lastname: Gantner
authors.forename: L E
authors.initials: LE
authors.lastname: Bruno-Blanch
authors.forename: E A
authors.initials: EA
authors.lastname: Castro
mesh_terms: D000818:Animals; D002490:Central Nervous System / Q000187:drug effects; D002491:Central Nervous System Agents / Q000737:chemistry* / Q000494:pharmacology*; D002493:Central Nervous System Diseases / Q000188:drug therapy*; D017076:Computer-Aided Design; D055808:Drug Discovery / Q000379:methods*; D006801:Humans
chemical_list: D002491:Central Nervous System Agents